Nanite Receives Funding to Employ SAYERTM Platform to Develop Non-Viral Delivery Vehicles to Express Neutralizing Antibodies In Vivo from the Bill & Melinda Gates Foundation

Nanite获得比尔和梅琳达·盖茨基金会的资助，利用SAYERTM平台开发非病毒载体，在体内表达中和抗体

BOSTON, May 8, 2024 /PRNewswire/ -- Nanite, Inc. today announced a $1.8M grant from the Bill & Melinda Gates Foundation to design and optimize polymeric delivery vehicles to deliver DNA-encoded therapeutics.

波士顿，2024年5月8日/PRNewswire/--Nanite，Inc.今天宣布，比尔和梅琳达·盖茨基金会（Bill＆MelindaGates Foundation）将拨款180万美元，用于设计和优化聚合物输送载体，以输送DNA编码的治疗剂。

Nanite's proprietary SAYERTM platform combines AI-driven polymer design with multiplexed in vivo screening to develop best-in-class polymer nanoparticles [PNPs] for tissue-specific delivery. SAYER has demonstrated strong delivery efficiency and high tissue specificity, potentially overcoming limitations of viral vectors and lipid nanoparticles [LNPs].

Nanite专有的SAYERTM平台将AI驱动的聚合物设计与多重体内筛选相结合，以开发用于组织特异性递送的同类最佳聚合物纳米颗粒（PNP）。SAYER已经证明了强大的递送效率和高组织特异性，可能克服病毒载体和脂质纳米颗粒（LNPs）的局限性。

In the research project funded by the foundation, Nanite will employ the SAYER platform to design and optimize polymeric delivery vehicles to deliver DNA-encoded therapeutics, thereby durably producing therapeutic antibodies in vivo. Success would represent a significant breakthrough in HIV management, particularly in populations with limited access to medical care..

在该基金会资助的研究项目中，Nanite将利用SAYER平台设计和优化聚合物递送载体，以递送DNA编码的治疗剂，从而在体内持久产生治疗性抗体。成功将是艾滋病毒管理的重大突破，特别是在获得医疗保健的人群中。。

'Nanite's research, with support from the Gates Foundation, is consequential in discovering safe polymeric nanoparticles for a transformative treatment for HIV,' notes Nanite Chief Business Officer, Thomas X. Neenan, PhD. 'One of our long-stated goals is to develop technologies that allow the benefits of gene therapy to be accessible to a wider patient population, particularly in underserved communities.

Nanite首席商务官托马斯·尼南（ThomasX.Neenan）博士指出，“Nanite的研究在盖茨基金会的支持下，对于发现用于艾滋病毒转化治疗的安全聚合物纳米粒子具有重要意义。”我们长期以来的目标之一是开发技术，使更广泛的患者群体，特别是在服务不足的社区，能够获得基因治疗的益处。

Nanite is dedicated to accelerating the impact of genetic medicine for the treatment of HIV.'.

Nanite致力于加速基因医学对艾滋病毒治疗的影响。”。

ABOUT NANITE:

关于NANITE：

Nanite, Inc. is a non-viral gene delivery company developing programmable, tissue-specific polymer nanoparticles (PNPs) for a broad range of modalities and indications. Powered by our AI-driven platform, SAYERTM, Nanite is building the next generation of non-viral delivery vehicles – programmable, targeted, and safe – for a new wave of genetic medicines.

Nanite，Inc.是一家非病毒基因传递公司，开发可编程的组织特异性聚合物纳米颗粒（PNP），用于广泛的模式和适应症。在人工智能驱动的SAYERTM平台的支持下，Nanite正在为新一波基因药物构建下一代非病毒载体-可编程，有针对性和安全性。

SAYER applies state-of-the-art machine learning-methods to combine high-throughput experimental and computational polymer chemistry to design fit-for-purpose delivery vehicles. Nanite is headquartered in Boston, MA. For more information, visit https://nanitebio.com..

SAYER应用最先进的机器学习方法，将高通量实验和计算聚合物化学相结合，以设计适合目的的运载工具。Nanite总部位于马萨诸塞州波士顿。有关更多信息，请访问https://nanitebio.com..

View original content to download multimedia:https://www.prnewswire.com/news-releases/nanite-awarded-1-8m-to-develop-ai-driven-gene-therapy-for-hiv-302138913.html

查看原始内容以下载多媒体：https://www.prnewswire.com/news-releases/nanite-awarded-1-8m-to-develop-ai-driven-gene-therapy-for-hiv-302138913.html

SOURCE Nanite Inc.

SOURCE Nanite公司。